1. Medtech Insight
  2. >>Policy & Regulation

More Specific Device Cost Data May Inform Medicare Inpatient Payments In FY 2014

CMS says it is finally ready to start relying on a specific cost-report line that it created five years ago for implantable devices, as well as distinct lines for cardiac catheterizations, CT scans and MRIs established more recently, to calculate hospital inpatient payments. It’s a positive for implantables and a negative for advanced imaging payments.

Medicare payments for inpatient implantable device procedures will get a boost if CMS goes through with its fiscal year 2014 proposal to rely on cost data more specific to those devices.

But a similar proposal from the Medicare agency would have a negative payment impact on certain imaging procedures that employ computed tomography and MRI.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Siemens Healthineers Widens FY25 EPS Range By €0.15 To Absorb Up To €300M In Tariff Costs

 
• By Shubham Singh

The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.